المؤلفون: Stephan Fuhrmann, Peter Brossart, Markus Munder, Mathias Hänel, Anja Seckinger, Katja Weisel, Hartmut Goldschmidt, Helga Bernhard, Jan Dürig, Anna Jauch, Martin Goerner, Christina Kunz, Hans-Walter Lindemann, Steffen Luntz, Ahmet H. Elmaagacli, Igor Wolfgang Blau, Hans Salwender, Maximilian Merz, Sandra Sauer, Marc S. Raab, Martin Hoffmann, Elias K. Mai, Kaya Miah, Axel Benner, Dirk Hose, Uta Bertsch, Christof Scheid

المساهمون: Hematology, Basic (bio-) Medical Sciences

المصدر: Leukemia

مصطلحات موضوعية: Adult, Male, Melphalan, Cancer Research, medicine.medical_specialty, Multiple Myeloma/drug therapy, Medizin, Myeloma, Induction Chemotherapy/mortality, Article, Bortezomib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Lenalidomide/administration & dosage, Humans, Medicine, Prospective Studies, Adverse effect, Lenalidomide, Multiple myeloma, Aged, Aged, 80 and over, business.industry, Correction, High dose melphalan, Consolidation Chemotherapy/mortality, Induction Chemotherapy, Hematology, Middle Aged, Prognosis, medicine.disease, Stem-cell research, Consolidation Chemotherapy, Survival Rate, Transplantation, Oncology, Toxicity, Randomized controlled trials, Bortezomib/administration & dosage, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Multiple Myeloma, business, Follow-Up Studies, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abdfae6314551f474fd5c284e7f37463
https://doi.org/10.1038/s41375-020-0976-9

المؤلفون: Martin Goerner, Markus Munder, Martin Hoffmann, Katja Weisel, Peter Brossart, Elias K. Mai, Anja Seckinger, Hans Salwender, Bernhard Rabold, Dirk Hose, Thomas Hielscher, Igor Wolfgang Blau, Uta Bertsch, Steffen Luntz, Ahmet H. Elmaagacli, Stefanie Huhn, Nicola Giesen, Hartmut Goldschmidt, Jens Hillengass, Marc S. Raab, Christina Kunz, Christof Scheid, Anna Jauch, Maximilian Merz, Diana Tichy, Barbara Hügle-Dörr, Hans-Walter Lindemann, Mathias Hänel, Helga Bernhard, Jan Dürig, Stephan Fuhrmann

المساهمون: Hematology, Basic (bio-) Medical Sciences

المصدر: Leukemia. 34:1853-1865

مصطلحات موضوعية: Male, 0301 basic medicine, Melphalan, Oncology, Cancer Research, Medizin, Dexamethasone, Cyclophosphamide/administration & dosage, Bortezomib, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Lenalidomide/administration & dosage, Medicine, Hematopoietic Stem Cell Transplantation/mortality, Prospective Studies, Lenalidomide, Multiple myeloma, education.field_of_study, Maintenance Chemotherapy/mortality, Remission Induction, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Prognosis, Combined Modality Therapy, Thalidomide, Survival Rate, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, medicine.drug, Dexamethasone/administration & dosage, Melphalan/administration & dosage, medicine.medical_specialty, Population, Transplantation, Autologous, Maintenance Chemotherapy, 03 medical and health sciences, Internal medicine, Internal Medicine, Humans, education, Cyclophosphamide, Survival rate, Aged, Thalidomide/administration & dosage, business.industry, Consolidation Chemotherapy/mortality, medicine.disease, Multiple Myeloma/pathology, Consolidation Chemotherapy, Transplantation, 030104 developmental biology, Bortezomib/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, business, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d3744d392b8b60be666bc6b8b4d70d
https://doi.org/10.1038/s41375-020-0724-1